JP Morgan Initiates Coverage On Nuvation Bio with Overweight Rating, Announces Price Target of $13

NUVATION BIO INC

NUVATION BIO INC

NUVB

0.00

JP Morgan analyst Priyanka Grover initiates coverage on Nuvation Bio (NYSE: NUVB) with a Overweight rating and announces Price Target of $13.